MEXICO CITY (March 24): Pharmaceutical company Merck is nearing a roughly US$6 billion all-cash deal to acquire biotech firm Terns Pharma, the Financial Times (FT) reported on Tuesday, citing people familiar with the matter. The potential acquisition comes as US-based Merck continues to reshape its oncology strategy. The company is in the process of establishing a dedicated cancer division centred around its blockbuster drug Keytruda, as it prepares for the drug's patent expiration in 2028. Merck and Terns Pharma did not immediately respond to Reuters' request for comment. Following the news, shares of Terns Pharma, which focuses on developing treatments for chronic myeloid leukemia, rose approximately 10% in after-hours trading.

Source: The Edge Markets March 25, 2026 03:00 UTC